{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}],"title":"Not Evaluable for Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Stable Disease > 2 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"10"}]}],"title":"Progressive Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"groups":[{"description":"Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.\n\nOncaspar, Doxil, Decadron: Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.","id":"OG000","title":"ODD Regimen"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"16 Weeks","title":"Study Specific Measure (Response)","type":"PRIMARY","unitOfMeasure":"participants"}